Schrödinger (SDGR) Aktievy
Schrödinger, Inc. utvecklar tillsammans med sina dotterbolag fysikbaserade beräkningsplattformar som möjliggör upptäckt av nya molekyler för läkemedelsutveckling och materialtillämpningar i USA, Asien-Stillahavsområdet, Europa, Mellanöstern, Afrika och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
SDGR Community Fair Values
Create NarrativeSee what 48 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$43.2
FV
56.8% undervärderad intrinsisk rabatt89
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Schrödinger, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$18.65 |
| 52 veckors högsta | US$23.02 |
| 52 veckors lägsta | US$10.95 |
| Beta | 1.66 |
| 1 månads förändring | 13.10% |
| 3 månaders förändring | 46.27% |
| 1 års förändring | -1.06% |
| 3 års förändring | -48.75% |
| 5 års förändring | -66.24% |
| Förändring sedan börsintroduktionen | -34.88% |
Senaste nyheter och uppdateringar
Analysartikel • Aug 08
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a pretty great week for Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders, with its shares surging 20% to...Seeking Alpha • Aug 04
Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It
Summary Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case. The base case delivers reasonable returns without any rerating, while the disruption playing out could see the stock multiply over the coming years - a genuinely asymmetric setup. Read the full article on Seeking AlphaRecent updates
Analysartikel • Aug 08
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a pretty great week for Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders, with its shares surging 20% to...Seeking Alpha • Aug 04
Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It
Summary Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case. The base case delivers reasonable returns without any rerating, while the disruption playing out could see the stock multiply over the coming years - a genuinely asymmetric setup. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jun 22
SDGR: Hosted Software Shift And 2026 Execution Progress Will Support Upside
Analysts have trimmed their average price target on Schrödinger, with recent cuts such as Morgan Stanley's move from $19 to $17. These revisions reflect updated assumptions around discount rates, profitability, and future P/E expectations.
Uppdatering av berättelse • Jun 08
SDGR: Reaffirmed 2026 Guidance Will Support Rerated Earnings Power
Analysts have trimmed their price targets on Schrödinger, with the updated fair value moving from $33.00 to $30.00. This reflects adjusted views on revenue growth, profit margins, and future P/E multiples following recent research updates that lowered Street targets to a range that includes $17 and $13.Uppdatering av berättelse • May 24
SDGR: Hosted Software Shift And 2026 Guidance Reset Will Support Upside
Analysts have trimmed the implied price target for Schrödinger stock by $0.50 to reflect a slightly lower fair value estimate of $20.88. This revision is informed by recent target cuts from several firms as they factor in updated assumptions around discount rates, revenue growth, profit margins and future P/E levels.Analysartikel • May 08
Analysts Have Lowered Expectations For Schrödinger, Inc. (NASDAQ:SDGR) After Its Latest Results
Shareholders of Schrödinger, Inc. ( NASDAQ:SDGR ) will be pleased this week, given that the stock price is up 11% to...
Uppdatering av berättelse • May 01
SDGR: Hosted Shift And 2026 Outlook Will Shape Risk Reward Balance
Narrative Update Overview Schrödinger's consensus analyst price target has moved to $13, with recent cuts from $18 and $24 as analysts factor in near term revenue pressure from the shift toward hosted software and adjust assumptions around growth, profitability, and valuation multiples. Analyst Commentary Recent research points to a more cautious tone around Schrödinger, with price targets moving lower as analysts factor in execution risk around the shift toward hosted software and its impact on reported revenue and valuation assumptions.Uppdatering av berättelse • Apr 17
SDGR: Hosted Software Shift And 2026 Booking Timing Will Drive Upside
Analysts have trimmed Schrödinger's implied fair value from $23.50 to $21.38 to reflect recent reductions in Street price targets as they recalibrate revenue growth expectations and factor in mixed views on the near term impact of the shift toward more hosted software. Analyst Commentary Recent research shows a clear reset in expectations around Schrödinger, with several firms lowering price targets while reassessing how the growing mix of hosted software could influence reported results and investor sentiment.Uppdatering av berättelse • Apr 03
SDGR: Hosted Software Transition Will Set Up 2026 Demand Reappraisal
Narrative Update on Schrödinger The average analyst price target for Schrödinger has reset toward $13, with recent cuts from $33 to $24, $28 to $25, $24 to $20, and $18 to $13 reflecting concerns about near term revenue pressure from the shift toward hosted software and ongoing debate about appropriate valuation multiples, even as analysts highlight stable demand indicators and maintain a mix of Buy, Overweight, Equal Weight, and Neutral views. Analyst Commentary Recent research on Schrödinger shows a cluster of price target resets and overall cautious positioning, even where ratings remain constructive.Uppdatering av berättelse • Mar 20
SDGR: Sector Pressures And Hosted Software Shift Will Reset 2026 Expectations
Schrödinger's analyst fair value has shifted from $18.00 to $13.00 as analysts recalibrated near term revenue growth assumptions, margin expectations, and future P/E multiples in light of recent price target reductions and commentary around hosted software and sector-wide valuation pressures. Analyst Commentary Recent Street research on Schrödinger has turned more cautious, with several bearish analysts trimming price targets as they reassess near term revenue recognition, margin outlook, and appropriate P/E multiples for the stock.Uppdatering av berättelse • Mar 06
SDGR: Hosted Software Shift Will Reshape Future Profitability Profile
Analysts have trimmed their average price target for Schrödinger from $27.30 to $23.50. The revision reflects updated views on the revenue impact of the shift toward hosted software, revised profit margin expectations, and a higher assumed future P/E multiple.Uppdatering av berättelse • Feb 19
SDGR: Sector Recovery And 2026 Guidance Will Reset Growth Expectations
Analysts have modestly reset their views on Schrödinger, with Street price targets clustering in an $18 to $25 range after recent revisions. This reflects a blend of sector-wide multiple compression, cautious sentiment on biotech and a preference for companies with clearer multi year growth frameworks.Uppdatering av berättelse • Feb 05
SDGR: Sector Recovery And 2026 Guidance Are Expected To Drive Upside
Analysts now set an average price target of about US$19 for Schrödinger, a roughly US$1 move from earlier blended expectations, reflecting mixed but generally constructive views that balance reduced targets from some firms with modest increases and new coverage focused on clearer multi year growth frameworks and sector recovery potential. Analyst Commentary Recent research updates on Schrödinger cluster around price targets in the high teens to mid twenties, with several firms adjusting their views as they recalibrate expectations for healthcare IT and small to mid cap biotech going into 2026.Analysartikel • Feb 04
With A 26% Price Drop For Schrödinger, Inc. (NASDAQ:SDGR) You'll Still Get What You Pay For
Unfortunately for some shareholders, the Schrödinger, Inc. ( NASDAQ:SDGR ) share price has dived 26% in the last thirty...Uppdatering av berättelse • Jan 22
SDGR: Sector Recovery Themes And 2026 Guidance Will Shape Balanced Outlook
Analysts have nudged their average price target on Schrödinger slightly higher to about $19, reflecting modestly stronger long term growth and margin assumptions, even as some firms trim near term targets to $24 and $25 and others initiate or lift targets around $18 to $19. Analyst Commentary Recent research on Schrödinger clusters around a tight band of price targets, mostly between $18 and $25, with differing opinions on how much upside remains relative to the current share price.Uppdatering av berättelse • Jan 07
SDGR: Future Outlook Will Balance Software Guidance With Catalyst Partnership Progress
Analysts have adjusted their price expectations for Schrödinger, citing updated assumptions around discount rates, revenue growth, profit margins, and a significantly higher future P/E multiple as the key drivers behind the revised target range and risk profile. What's in the News Schrödinger updated its financial guidance for the year ending December 31, 2025, with software revenue growth now expected in a range of 8% to 13%, compared with a prior range of 10% to 15% (Corporate Guidance).Uppdatering av berättelse • Dec 16
SDGR: Future Outlook Will Hinge On Software Momentum And Pipeline Data
Analysts have modestly reduced their price target on Schrödinger from $19.00 to $18.00 per share, reflecting a more cautious view on near term revenue growth and margins amid limited visibility on software growth and pending validation from early stage pipeline data. Analyst Commentary Recent research commentary underscores a more balanced but guarded stance on Schrödinger, with the stock viewed as needing further proof points on both its software growth trajectory and its internal pipeline productivity.Analysartikel • Nov 23
What You Can Learn From Schrödinger, Inc.'s (NASDAQ:SDGR) P/S After Its 27% Share Price Crash
Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders won't be pleased to see that the share price has had a very rough month...Analysartikel • Nov 08
Analysts Are Updating Their Schrödinger, Inc. (NASDAQ:SDGR) Estimates After Its Third-Quarter Results
As you might know, Schrödinger, Inc. ( NASDAQ:SDGR ) just kicked off its latest third-quarter results with some very...Uppdatering av berättelse • Aug 16
Pipeline And Predictive Toxicology Will Unlock Future Success
Schrödinger’s consensus price target has been revised downward to $28.20, reflecting analyst concerns over disappointing progress in its proprietary drug portfolio and broader sector headwinds, partially offset by steady performance in its software business. Analyst Commentary Bearish analysts expressed concerns over disappointing updates from Schrodinger's proprietary drug portfolio, particularly lackluster progress in its early Phase 1 assets, which were previously anticipated to attract significant partner interest.Analysartikel • Apr 28
Schrödinger, Inc. (NASDAQ:SDGR) Looks Just Right With A 33% Price Jump
Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders would be excited to see that the share price has had a great month...Analysartikel • Mar 27
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 46% Undervalued
Key Insights The projected fair value for Schrödinger is US$38.44 based on 2 Stage Free Cash Flow to Equity Current...
Ny berättelse • Mar 23
Partnerships With Novartis And Lilly Will Strengthen Future Prospects
Expansion in software and partnerships with pharmaceutical giants is expected to boost revenue and margins significantly.Seeking Alpha • Mar 02
Schrödinger: Still Waiting On A Catalyst
Summary Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing. Schrödinger appears attractively priced given the strength of its software business and growing drug discovery business. Despite this, I don't expect the stock to rerate until the company has meaningful clinical success. Read the full article on Seeking AlphaAnalysartikel • Feb 28
What Does Schrödinger, Inc.'s (NASDAQ:SDGR) Share Price Indicate?
Schrödinger, Inc. ( NASDAQ:SDGR ), is not the largest company out there, but it saw a double-digit share price rise of...Seeking Alpha • Feb 15
Schrödinger: An Interesting Investment With Immense Potential
Summary SDGR has reported financial losses in five of the last six years. In 2025, the company will report the results of its three experimental drugs that are in Phase 1 of clinical trials. The results will clarify the perspective of SDGR. The losses that SDGR has reported were due to the expenses that it has incurred to implement trials of its three experimental drugs. Read the full article on Seeking AlphaAnalysartikel • Jan 25
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 25% Higher
Schrödinger, Inc. ( NASDAQ:SDGR ) shares have continued their recent momentum with a 25% gain in the last month alone...Analysartikel • Jan 06
Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Nov 21
Schrödinger: Positive Signs Despite The Share Price Decline
Summary Schrödinger's growth was soft in the third quarter, and the company's losses continue to grow due to investments in internal programs. Operating expenses are expected to level out going forward, though, and Schrödinger should soon return to YoY growth. Despite short-term investor skepticism, the Novartis deal and progress by partners further validate Schrödinger's approach to drug discovery. While Schrödinger is deeply undervalued and has sufficient cash to continue advancing internal programs, positive clinical data will likely be needed for the stock to rise. Read the full article on Seeking AlphaAnalysartikel • Nov 13
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher
Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Oct 17
Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty
Summary Schrödinger's stock has fallen 64% since January 2023, driven by missed revenue and EPS targets, despite ongoing AI-powered drug discovery efforts. Financial health remains stable with a current ratio over 2 and a cash runway of approximately 2 years, despite significant net losses and high R&D investments. The company's proprietary pipeline, including SGR-1505 for B-cell malignancies, faces significant competition and must deliver convincing safety and efficacy data. Maintain "hold" rating due to high operational and financial risks, despite promising AI prospects and a more palatable valuation. Read the full article on Seeking AlphaAnalysartikel • Sep 27
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues
Schrödinger, Inc.'s ( NASDAQ:SDGR ) price-to-sales (or "P/S") ratio of 6.9x may look like a poor investment opportunity...Seeking Alpha • Aug 06
Schrodinger: More Drug Discovery Validation
Summary Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for Schrodinger's approach to drug discovery. Schrodinger's stock remains under pressure due to mounting losses and market jitters though. While Schrodinger is undervalued, investors will likely need to see more evidence of drug discovery success before the stock moves higher. Read the full article on Seeking AlphaAnalysartikel • Aug 05
Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysartikel • Jun 12
We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right
Key Insights Schrödinger's Annual General Meeting to take place on 18th of June Total pay for CEO Ramy Farid includes...Seeking Alpha • May 07
Schrödinger: More Pharmaceutical Than Software
Summary Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, despite the company progressing drug candidates into clinical trials. While Schrödinger's valuation is attractive, investors are focused on the company's large losses and modest growth. Clinical success may be required before Schrödinger's various ventures are appropriately valued. Read the full article on Seeking AlphaAnalysartikel • May 02
Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar
When you see that almost half of the companies in the Healthcare Services industry in the United States have...Analysartikel • Mar 01
Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially
Market forces rained on the parade of Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders today, when the analysts...Seeking Alpha • Mar 01
Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024
Summary Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth amongst smaller customers particularly soft. Losses associated with the drug discovery business could continue to weigh on the stock in the near-term. As Schrodinger's proprietary and collaboration programs progress through clinical trials, the stock price is more likely to reflect the true value of Schrodinger's various activities. Read the full article on Seeking AlphaAktieägarnas avkastning
| SDGR | US Healthcare Services | US Marknad | |
|---|---|---|---|
| 7D | 19.2% | 12.8% | 2.2% |
| 1Y | -1.1% | -22.9% | 20.9% |
Avkastning vs industri: SDGR översteg US Healthcare Services branschen som gav -22.9 % under det senaste året.
Avkastning vs Marknaden: SDGR presterade sämre än US marknaden som gav 20.9 % under det senaste året.
Prisvolatilitet
| SDGR volatility | |
|---|---|
| SDGR Average Weekly Movement | 7.5% |
| Healthcare Services Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: SDGR har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: SDGR s veckovolatilitet ( 8% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1990 | 850 | Ramy Farid | www.schrodinger.com |
Schrödinger, Inc. utvecklar tillsammans med sina dotterbolag fysikbaserade beräkningsplattformar som möjliggör upptäckt av nya molekyler för läkemedelsutveckling och materialtillämpningar i USA, Asien-Stillahavsområdet, Europa, Mellanöstern, Afrika och internationellt. Bolaget är verksamt inom två segment, Software och Drug Discovery. Software-segmentet säljer sin programvara för att omvandla molekylär upptäckt för life science- och materialvetenskapsindustrier.
Schrödinger, Inc. Sammanfattning av grunderna
| SDGR grundläggande statistik | |
|---|---|
| Börsvärde | US$1.40b |
| Vinst(TTM) | -US$54.33m |
| Intäkter(TTM) | US$259.04m |
5.4x
P/S-förhållande-25.7x
P/E-förhållandeÄr SDGR övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SDGR resultaträkning (TTM) | |
|---|---|
| Intäkter | US$259.04m |
| Kostnad för intäkter | US$111.72m |
| Bruttovinst | US$147.31m |
| Övriga kostnader | US$201.65m |
| Intäkter | -US$54.33m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.73 |
| Bruttomarginal | 56.87% |
| Nettovinstmarginal | -20.98% |
| Skuld/egenkapitalförhållande | 0% |
Hur har SDGR utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/11 02:19 |
| Aktiekurs vid dagens slut | 2026/08/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Schrödinger, Inc. bevakas av 18 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Gaurav Goparaju | Berenberg |
| Clarence Powell | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |